IGM Biosciences, Inc.
NASDAQ:IGMS
Overview | Financials
Company Name | IGM Biosciences, Inc. |
Symbol | IGMS |
Currency | USD |
Price | 6.65 |
Market Cap | 394,553,478 |
Dividend Yield | 0% |
52-week-range | 6.129 - 22.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Fred M. Schwarzer J.D. |
Website | https://igmbio.com |
An error occurred while fetching data.
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD